Oncimmune to publish full year results on 30th October 2020

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, will be announcing its full year results for the year ended 31 May 2020 on Friday, 30 October 2020.

Adam Hill, Chief Executive Officer, together with Matthew Hall, Chief Financial Officer, will host a presentation and conference call for analysts at 11:30am GMT on the day of the results.

For conference call details please contact Alexander Davis of FTI Consulting at Alexander.Davis@fticonsulting.com or 020 3727 1000.

The management team will also host on Investor Meet Company a live presentation of the results on Friday, 30 October at 15:00 GMT.

•     The online presentation will be open to all existing shareholders and potential new investors.

•     Questions can be submitted before the event via your Investor Meet Company dashboard or at any time during the live presentation via the “Ask a Question” function. Responses to the Q&A will be published at the earliest opportunity on the Investor Meet Company platform.

•     Investor feedback can also be submitted directly to management immediately following the event.

Access to Investor Meet Company is free and interested parties can register to attend the presentation via the following link: https://www.investormeetcompany.com/essensys-plc/register-investor 

Attendees who have already registered on the Investor Meet Company platform to meet the Company will automatically receive an invitation to the presentation.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn

    More articles like this

    Oncimmune’s EarlyCDT Lung blood test featured on ITV News

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has noted the national ITV News1 feature last weekend on Oncimmune’s EarlyCDT® Lung blood test titled “New Blood Test Provides Breakthrough in Lung Cancer Detection Rates”. The news feature

    Oncimmune Roche contract expansion

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group,has announced that Roche has exercised its option to increase the scope and value of the cornerstone contract announced on 28 May 2020. Since the announcement, Oncimmune has

    Zeus Capital

    Oncimmune NICE validation of EarlyCDT Lung

    Positive outcomes following the UK’s National Institute for Health and Care Excellence (NICE) review of Oncimmune Holdings (LON:ONC) EarlyCDT Lung diagnostic test, provides clear external validation for its incorporation into care pathways, and carries weight in